Fennec Pharmaceuticals (FENC) Interest Coverage Ratio (2014 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Interest Coverage Ratio came in at 1.07 in Q4 2025, up 17.78% YoY from 0.91 in Q4 2024, and down 231.61% on a QoQ basis from 0.32 in Q3 2025.
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 10 years of Interest Coverage Ratio data on file, last reported at 1.07 in Q4 2025.
- Quarterly Interest Coverage Ratio rose 17.78% year-over-year to 1.07 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1.51 (down 324.73% YoY) and the FY2025 annual result came in at 0.14, down 375.4% from the prior year.
- Interest Coverage Ratio slipped to 1.07 in Q4 2025, from 0.32 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 13.29 in Q1 2024 to a low of 1230.75 in Q1 2021.
- A 5-year average of 83.44 and a median of 5.37 in 2023 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio sank 63064.22% — and 2024, when it surged 301.26%.
- Tracing FENC's Interest Coverage Ratio over 5 years: stood at 67.85 in 2021, then soared by 87.85% to 8.25 in 2022, then soared by 75.9% to 1.99 in 2023, then soared by 34.53% to 1.3 in 2024, then grew by 17.78% to 1.07 in 2025.
- The last three Interest Coverage Ratio figures came in at 1.07 (Q4 2025), 0.32 (Q3 2025), and 4.6 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn | 579.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 579.00 |
| Dec 31, 2025 | -8.29 |
| Sep 30, 2025 | -0.32 |
| Jun 30, 2025 | -4.60 |
| Mar 31, 2025 | -1.36 |
| Dec 31, 2024 | -0.97 |
| Sep 30, 2024 | -5.08 |
| Jun 30, 2024 | -4.83 |
| Mar 31, 2024 | 13.29 |
| Dec 31, 2023 | -1.99 |
| Sep 30, 2023 | -1.19 |
| Jun 30, 2023 | -5.66 |
| Mar 31, 2023 | -6.60 |
| Dec 31, 2022 | -8.25 |
| Sep 30, 2022 | -66.38 |
| Jun 30, 2022 | -87.88 |
| Mar 31, 2022 | -61.14 |
| Dec 31, 2021 | -67.85 |
| Sep 30, 2021 | -75.87 |
| Jun 30, 2021 | -435.56 |